Tempus AI, Inc.

TEM

Held by 2 specialist biotech funds

Share on X

Fund Holdings

RTW Investments Casdin Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

RTW InvestmentsNEWFeb 17, 2026

Shares: 200,000Value: $11.8M

RTW's $11.8M entry into Tempus AI signals confidence in AI-driven oncology drug discovery at a critical inflection point—the company's proprietary platform has generated internal pipeline candidates moving toward IND filings. The timing aligns with Tempus's transition from software/data plays toward clinical-stage assets, where Wong's track record of backing early-stage biotech suggests conviction in near-term catalysts (likely IND applications within 12-18 months).

Casdin CapitalNEWFeb 17, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NGNE2 funds TSHA2 funds BEAM2 funds GPCR2 funds GH2 funds NBIX1 fund CI1 fund FDMT1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Casdin Capital Initiates Tempus AI Position Casdin's $17.4M entry into TEM signals conviction in AI-driven oncology diagnostics at a time when the company is scaling clinical adoption and pursuing FDA clearances for proprietary assays. The position timing coincides with accelerating validation of Tempus's machine learning models in solid tumors and potential near-term regulatory milestones that could unlock enterprise/payer reimbursement. This represents Casdin's core thesis on precision medicine infrastructure rather than single-asset risk.